Literature DB >> 18953440

PI3K/Akt pathway activation attenuates the cytotoxic effect of methyl jasmonate toward sarcoma cells.

Uri Elia1, Eliezer Flescher.   

Abstract

Methyl jasmonate (MJ) acts both in vitro and in vivo against various cancer cell lines. Activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway results in decreased susceptibility to cytotoxic agents in many types of cancer cells. We found a strong inverse correlation between the basal level of phospho-Akt (pAkt) and the sensitivity to MJ among sarcoma cell lines. Nevertheless, levels of pAkt increased in two sarcoma cell lines, MCA-105 and SaOS-2, after MJ treatment. Treatment of both cell lines with PI3K/Akt pathway inhibitors in combination with MJ resulted in a synergistic cytotoxic effect. Moreover, cells transfected with a constitutively active Akt were less susceptible to MJ-induced cytotoxicity in comparison with cells transfected with an inactive form of Akt. Taken together, these data suggest that the increase in pAkt after treatment with MJ played a protective role. Because it has been shown that the antiapoptotic effects of Akt are dependent on glycolysis, we examined the role of glucose metabolism in activation of Akt and the subsequent resistance of the cell lines to MJ. 2-Deoxy-d-glucose, a glycolysis inhibitor, decreased the levels of pAkt and was able to attenuate the MJ-induced elevation in pAkt. Accordingly, the presence of glucose attenuated MJ-induced cytotoxicity. Moreover, treatment with 2-deoxy-d-glucose in combination with MJ resulted in a synergistic cytotoxic effect. In conclusion, the PI3K/Akt pathway plays a critical role in the resistance of MCA-105 and SaOS-2 sarcoma cell lines toward MJ-induced cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18953440      PMCID: PMC2570607          DOI: 10.1593/neo.08636

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  63 in total

1.  The phosphatidylinositide 3'-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C.

Authors:  A Tenzer; D Zingg; S Rocha; B Hemmings; D Fabbro; C Glanzmann; P A Schubiger; S Bodis; M Pruschy
Journal:  Cancer Res       Date:  2001-11-15       Impact factor: 12.701

2.  Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.

Authors:  J Brognard; A S Clark; Y Ni; P A Dennis
Journal:  Cancer Res       Date:  2001-05-15       Impact factor: 12.701

3.  Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis.

Authors:  A Nesterov; X Lu; M Johnson; G J Miller; Y Ivashchenko; A S Kraft
Journal:  J Biol Chem       Date:  2001-01-18       Impact factor: 5.157

4.  Akt and Bcl-xL promote growth factor-independent survival through distinct effects on mitochondrial physiology.

Authors:  D R Plas; S Talapatra; A L Edinger; J C Rathmell; C B Thompson
Journal:  J Biol Chem       Date:  2001-01-12       Impact factor: 5.157

5.  Akt is activated in response to an apoptotic signal.

Authors:  D Tang; H Okada; J Ruland; L Liu; V Stambolic; T W Mak; A J Ingram
Journal:  J Biol Chem       Date:  2001-06-08       Impact factor: 5.157

6.  Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase.

Authors:  K Gottlob; N Majewski; S Kennedy; E Kandel; R B Robey; N Hay
Journal:  Genes Dev       Date:  2001-06-01       Impact factor: 11.361

7.  3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth.

Authors:  Y Hu; L Qiao; S Wang; S B Rong; E J Meuillet; M Berggren; A Gallegos; G Powis; A P Kozikowski
Journal:  J Med Chem       Date:  2000-08-10       Impact factor: 7.446

8.  Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt.

Authors:  L del Peso; M González-García; C Page; R Herrera; G Nuñez
Journal:  Science       Date:  1997-10-24       Impact factor: 47.728

9.  Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine).

Authors:  Saori Sato; Naoya Fujita; Takashi Tsuruo
Journal:  Oncogene       Date:  2002-03-07       Impact factor: 9.867

10.  Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients.

Authors:  G Pérez-Tenorio; O Stål
Journal:  Br J Cancer       Date:  2002-02-12       Impact factor: 7.640

View more
  16 in total

1.  Strigolactones: a novel class of phytohormones that inhibit the growth and survival of breast cancer cells and breast cancer stem-like enriched mammosphere cells.

Authors:  C B Pollock; H Koltai; Y Kapulnik; C Prandi; R I Yarden
Journal:  Breast Cancer Res Treat       Date:  2012-03-29       Impact factor: 4.872

2.  Dinosaurs and ancient civilizations: reflections on the treatment of cancer.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2010-12       Impact factor: 5.715

3.  Hypoxia enhances glucocorticoid-induced apoptosis and cell cycle arrest via the PI3K/Akt signaling pathway in osteoblastic cells.

Authors:  Wanjing Zou; Shu Yang; Tie Zhang; Haimei Sun; Yuying Wang; Hong Xue; Deshan Zhou
Journal:  J Bone Miner Metab       Date:  2014-09-18       Impact factor: 2.626

4.  The War on Cancer rages on.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

5.  Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas.

Authors:  Kaiji Hu; Cathy Lee; Dexin Qiu; Abbas Fotovati; Alastair Davies; Samah Abu-Ali; Daniel Wai; Elizabeth R Lawlor; Timothy J Triche; Catherine J Pallen; Sandra E Dunn
Journal:  Mol Cancer Ther       Date:  2009-11-03       Impact factor: 6.261

6.  Neoplasia: the second decade.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

Review 7.  Metabolic interplay between glycolysis and mitochondrial oxidation: The reverse Warburg effect and its therapeutic implication.

Authors:  Minjong Lee; Jung-Hwan Yoon
Journal:  World J Biol Chem       Date:  2015-08-26

8.  Strigolactones-a novel class of phytohormones as anti-cancer agents.

Authors:  Mohammed Nihal Hasan; Syed S I Razvi; Abudukadeer Kuerban; Khadijah Saeed Balamash; Widad M Al-Bishri; Khalid Omar Abulnaja; Hani Choudhry; Jehan A Khan; Said Salama Moselhy; Zamzami M; Taha A Kumosani; Abdulrahman L Al-Malki; Mahmoud Alhosin; Tadao Asami
Journal:  J Pestic Sci       Date:  2018-08-20       Impact factor: 1.519

9.  CYLD negatively regulates transforming growth factor-β-signalling via deubiquitinating Akt.

Authors:  Jae Hyang Lim; Hirofumi Jono; Kensei Komatsu; Chang-Hoon Woo; Jiyun Lee; Masanori Miyata; Takashi Matsuno; Xiangbin Xu; Yuxian Huang; Wenhong Zhang; Soo Hyun Park; Yu-Il Kim; Yoo-Duk Choi; Huahao Shen; Kyung-Sun Heo; Haodong Xu; Patricia Bourne; Tomoaki Koga; Haidong Xu; Chen Yan; Binghe Wang; Lin-Feng Chen; Xin-Hua Feng; Jian-Dong Li
Journal:  Nat Commun       Date:  2012-04-10       Impact factor: 14.919

Review 10.  Jasmonate Compounds and Their Derivatives in the Regulation of the Neoplastic Processes.

Authors:  Iwona Jarocka-Karpowicz; Agnieszka Markowska
Journal:  Molecules       Date:  2021-05-13       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.